Protein C biologic approved for clotting disorder

April 9, 2007

Patients with protein C deficiency will now have a new treatment available to them

Patients with protein C deficiency will now have a new treatment available to them. Baxter Healthcare has announced the approval of Ceprotin, the first biologic to treat the condition. The new therapy is a concentrated form of protein C made from the plasma of healthy human blood donors. Normally, the protein is manufactured in the liver and helps control coagulation by preventing the formation of blood clots. Patients with low levels of protein C experience abnormally high numbers of blood clots. Ceprotin is indicated for patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. The biologic was granted orphan drug status by the FDA and was approved under a priority review schedule.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.